Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carol Pollock

Showing results (101-110 of 162) with videos related to

Pageof 17
Sort By:
Kidney360|July 25, 2024
Hyperkalemia Burden and Treatment Pathways in Patients with CKD: Findings From the DISCOVER CKD Retrospective CohortSteven Fishbane, Juan-Jesus Carrero, Supriya Kumar, et al.
Diabetes Care|September 15, 2020
Therapy Escalation Following an Elevated HbA<sub>1c</sub> in Adults Aged 45 Years and Older Living With Diabetes in Australia: A Real-World Observational AnalysisYing Xie, Jannah Baker, Tamara Young, et al.
Diabetes, Obesity & Metabolism|October 12, 2020
Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomesBrendon L Neuen, Clare Arnott, Vlado Perkovic, et al.
Advances in Therapy|November 29, 2024
Baseline Characteristics of the DISCOVER CKD Prospective CohortCarol Pollock, Juan-Jesus Carrero, Eiichiro Kanda, et al.
Diabetes, Obesity & Metabolism|November 6, 2020
Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendationsChin Meng Khoo, Chaicharn Deerochanawong, Siew Pheng Chan, et al.
BMJ Open|January 6, 2026
Hemopurifier device in patients with solid tumours who have stable or progressive disease while on a treatment that includes pembrolizumab or nivolumab: protocol for an Australian safety, feasibility and dose-finding studyMichael P Brown, Marco Matos, Stephen Clarke, et al.
Advances in Therapy|February 3, 2025
Correction: Baseline Characteristics of the DISCOVER CKD Prospective CohortCarol Pollock, Juan-Jesus Carrero, Eiichiro Kanda, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 4, 2025
Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: Insights from the CREDENCE trialBryony Beal, Luke Buizen, Emily K Yeung, et al.
Diabetes, Obesity & Metabolism|November 8, 2024
Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?Tamara Y Milder, Jialing Lin, Sallie-Anne Pearson, et al.
Internal Medicine Journal|October 4, 2020
Risk factors for incident kidney disease in older adults: an Australian prospective population-based studyAmy Kang, Louisa Sukkar, Carinna Hockham, et al.
Pageof 17

Showing results (101-110 of 162) with videos related to

Sort By:
Pageof 17
Kidney360|July 25, 2024
Hyperkalemia Burden and Treatment Pathways in Patients with CKD: Findings From the DISCOVER CKD Retrospective CohortSteven Fishbane, Juan-Jesus Carrero, Supriya Kumar, et al.
Diabetes Care|September 15, 2020
Therapy Escalation Following an Elevated HbA<sub>1c</sub> in Adults Aged 45 Years and Older Living With Diabetes in Australia: A Real-World Observational AnalysisYing Xie, Jannah Baker, Tamara Young, et al.
Diabetes, Obesity & Metabolism|October 12, 2020
Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomesBrendon L Neuen, Clare Arnott, Vlado Perkovic, et al.
Advances in Therapy|November 29, 2024
Baseline Characteristics of the DISCOVER CKD Prospective CohortCarol Pollock, Juan-Jesus Carrero, Eiichiro Kanda, et al.
Diabetes, Obesity & Metabolism|November 6, 2020
Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendationsChin Meng Khoo, Chaicharn Deerochanawong, Siew Pheng Chan, et al.
BMJ Open|January 6, 2026
Hemopurifier device in patients with solid tumours who have stable or progressive disease while on a treatment that includes pembrolizumab or nivolumab: protocol for an Australian safety, feasibility and dose-finding studyMichael P Brown, Marco Matos, Stephen Clarke, et al.
Advances in Therapy|February 3, 2025
Correction: Baseline Characteristics of the DISCOVER CKD Prospective CohortCarol Pollock, Juan-Jesus Carrero, Eiichiro Kanda, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 4, 2025
Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: Insights from the CREDENCE trialBryony Beal, Luke Buizen, Emily K Yeung, et al.
Diabetes, Obesity & Metabolism|November 8, 2024
Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?Tamara Y Milder, Jialing Lin, Sallie-Anne Pearson, et al.
Internal Medicine Journal|October 4, 2020
Risk factors for incident kidney disease in older adults: an Australian prospective population-based studyAmy Kang, Louisa Sukkar, Carinna Hockham, et al.
Pageof 17